You are here: Industry Insights > Eli Lilly

News List

Eli Lilly’s BAQSIMI nasal powder set to treat severe hypoglycemia biospectrumasia
July 28, 2019
It is compact, portable and ready to use (no reconstitution required) in a single, fixed, 3 mg dose
Eli Lilly's Taltz touts long-term clear skin data after unimpressive first-quarter sales fiercepharma
June 12, 2019
After undershooting analyst sales forecasts in the first quarter, Eli Lilly’s psoriasis drug Taltz is on the hot seat in an immunology market packed with blockbusters.
Half-Price Version of Humalog Insulin Now Available drugs
May 23, 2019
A half-price version of Humalog insulin is now available in the United States, Eli Lilly said Wednesday.
Innovent Biologics, Eli Lilly has announced that IBI301 has met pre-defined primary endpoints biospectrumasia
May 09, 2019
The details of these studies will be disclosed in future publications in scientific journals and conferences.
Lilly to focus on new drugs in China, unload antibiotics brands and manufacturing facility for $375M fiercepharma
April 24, 2019
Eli Lilly is taking one step out of China so it can gain a firmer foothold with the other. Amid a national clampdown on antibiotics overuse, the U.S. pharma is selling Chinese rights to two legacy antibiotics and a manufacturing facility in a deal worth $
Positive results for Eli Lilly’s Taltz in late stage non-radiographic axial spondyloarthritis trial pharmatimes
April 24, 2019
Eli Lilly has announced that its humanised monoclonal antibody, Taltz (ixekizumab), yielded good results in a Phase III trial.
Eli Lilly, Avidity Biosciences announce $35M immunology research deal pharmatimes
April 24, 2019
The US Food and Drug Administration (FDA) has approved MSD’s Keytruda (pembrolizumab), in combination with Inlyta(axitinib), as first-line treatment for patients with advanced renal cell carcinoma (RCC).
Eli Lilly Sells Two Legacy Drugs and Manufacturing Facility in China for $375M biospace
April 24, 2019
Eli Lilly has inked a $375 million deal with China-based Eddingpharm for the rights to two legacy antibiotic medicines and manufacturing facility in Suzhou, China.
Pfizer and Lilly announce top-line results from long-term Phase 3 study of tanezumab in patients with osteoarthritis worldpharmanews
April 23, 2019
Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) announced top-line results from a Phase 3 study evaluating tanezumab 2.5 mg and 5 mg.
Pfizer, Eli Lilly's tanezumab yields mixed results in Phase III osteoarthritis trial firstwordpharma
April 21, 2019
Pfizer and Eli Lilly announced top-line results showing that the high dose of the NGF inhibitor tanezumab met two of three co-primary efficacy endpoints in a Phase III study……

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page